RecruitingNCT06926829
Long-term safety of EB-1020 after an earlier adult ADHD trial
About this title
Read the official source — NCT06926829Researchers are comparing EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg, tracking side effects to assess long-term safety in adults with ADHD.
Medication studyAges 18–55Japan
Understand this study
What is this study about?
Researchers are comparing EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg, tracking side effects to assess long-term safety in adults with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
What will I do during this study?
You take the study medication EB-1020 (centanafadine) as an oral capsule once daily for 52 weeks. The study groups receive different dose levels.
- Listed locations
- TokyoSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Treatment duration
- 52 weeks
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 25, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06926829
- Official title
Show the full official title
A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Trial to Evaluate the Safety and Efficacy of Long-term Administration of EB-1020 Once Daily QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Tokyo
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg, tracking side effects to assess long-term safety in adults with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg.
Who can participate?
This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
